The intent of the India Trial is to gather preliminary safety and efficacy data that could be pertinent to Vivo's pending IDE submission to the FDA, NOT to ""cure"" those patients.
That was made evidently clear by the type of patients that were selected, ie, those with few or no other treatment options available for their persistent ailment.
The fact that you keep accusing others of lying all the while blatantly lying yourself simply proves how much of an utter fraud, with an obvious agenda, you are!
ema_lurker DD @ Stock twits...........
1. Trial Overview and Design
Phase 1/2 Study: The trial is focused on testing the safety and initial efficacy of RadioGel™ for treating solid metastatic tumors in lymph nodes.
2. Target Patient Population
Inclusion Criteria:
Patients with recurrent or metastatic solid tumors in lymph nodes, who are poor candidates for surgery or external beam radiation.
#SCEEATE
Market Data 
Markets 
AI
